Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
9ywgpAKT1c1KgUuB